Karnataka seeks central action on massive drug price gaps at 254 firms
Karnataka's Food and Drug Administration has asked the central government to intervene against 254 pharmaceutical companies over extreme disparities between hospital procurement costs and patient prices.
Karnataka's Food and Drug Administration has formally requested central intervention against 254 drug manufacturers, citing stark differences between the costs at which hospitals acquire medicines and the maximum retail prices charged to patients. The FDA forwarded the pricing information to the National Pharmaceutical Pricing Authority and the Central Drugs Control Agency, seeking action under the Drugs (Prices Control) Order, 2013, and proposing limits on trade margins for medicines, devices, and consumables.
Specific cases show procurement prices of less than ₹200 contrasted with MRPs above ₹4,000, including several injectable oncology drugs with gaps up to more than 70 times. Officials said hospitals often receive medicines at reduced institutional rates but bill patients at or near the printed MRP, especially in emergency, intensive-care, oncology, kidney and AIDS treatments. The state also pointed to hidden commercial arrangements such as rebates and credit notes that lower hospital acquisition costs without patient visibility. Karnataka proposes a national framework and detailed itemised billing to cap patient charges and increase transparency.
Why it matters
Unchecked drug price mark-ups can make essential medicines unaffordable for patients needing urgent treatment.
How the sides frame it
LOW AGREEMENTLeft-leaning coverage centers on Karnataka’s FDA seeking central intervention to curb massive price gaps between hospital procurement costs and patient MRPs, while centrist coverage highlights a separate survey of Maharashtra’s FDA exposing huge mark-ups on consumables and urges clearer guidelines for cashless insurance claims.
LEFT
Frames the story as a state-level push for federal regulation to address extreme drug price disparities and limit trade margins.
CENTER
Frames the story as an exposé of inflated medical consumable prices and a call for policy guidance on cashless health-insurance billing.
The left emphasises
- Karnataka FDA has formally requested central action against 254 drug manufacturers.
- procurement prices as low as ₹200 versus MRPs above ₹4,000, with some oncology drugs over 70-times higher.
- proposes limits on trade margins for medicines, devices, and consumables.
In this story
